Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

Ronald Boellaard, Roberto Delgado-Bolton, Wim J.G. Oyen, Francesco Giammarile, Klaus Tatsch, Wolfgang Eschner, Fred J. Verzijlbergen, Sally F. Barrington, Lucy C. Pike, Wolfgang A. Weber, Sigrid Stroobants, Dominique Delbeke, Kevin J. Donohoe, Scott Holbrook, Michael M. Graham, Giorgio Testanera, Otto S. Hoekstra, Josee Zijlstra, Eric Visser, Corneline J. HoekstraJan Pruim, Antoon Willemsen, Bertjan Arends, J??rg Kotzerke, Andreas Bockisch, Thomas Beyer, Arturo Chiti, Bernd J. Krause, Ana E. Brito, Allan Santos, André Deeke Sasse, Cesar Cabello, Paulo Oliveira, Camila Mosci, Tiago Souza, Barbara Amorim, Mariana Lima, Celso D. Ramos, Elba Etchebehere, Stephanie A Harmon, Timothy Perk, Chieh Christie Lin, Jens Eickhoff, Peter L. Choyke, William L. Dahut, B Andrea, John L. Humm, Steven M Larson, Michael J. Morris, Glenn Liu, Robert Jeraj, T. Bradshaw, Timothy Perk, Stephanie A Harmon, Jens Eickhoff, N. Jallow, Peter L. Choyke, William L. Dahut, Steven M Larson, John L. Humm, S. Perlman, A. B. Apolo, Michael J. Morris, Glenn Liu, Robert Jeraj, Emmanuel Itti, Corinne Haioun, Yolande Petegnief, Alain Luciani, Jehan Dupuis, Gaetano Paone, Jean-Noël Talbot, Alain Rahmouni, Michel Meignan, Brett Marinelli, Carina Espinet-Col, Gary A Ulaner, Heather L McArthur, Mithat Gonen, Maxine Jochelson, Wolfgang A. Weber, Iain Murray, Sarah J. Chittenden, Ana M. Denis-Bacelar, Cecilia Hindorf, Christopher C. Parker, Sue Chua, Glenn D. Flux

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

51 Citations (Scopus)


PURPOSE In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease. RESULTS Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p <0.0001) and progression free-survival (p <0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448). MATERIALS AND METHODS We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months. CONCLUSIONS 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.
Original languageEnglish
Title of host publicationEuropean Journal of Nuclear Medicine and Molecular Imaging
PublisherEuropean Journal of Nuclear Medicine and Molecular Imaging
Number of pages27
ISBN (Print)1535-5667 (Electronic)\r0161-5505 (Linking)
Publication statusPublished - 2017

Publication series

NameEuropean Journal of Nuclear Medicine and Molecular Imaging


  • -Fluoride
  • 10
  • 116
  • 177295
  • 1872
  • 1879
  • 18F
  • 223Ra
  • 2967
  • 57
  • Absorbed dose
  • Alpha emitter
  • FDG
  • Imaging procedure
  • NaF PET/CT
  • Oncology
  • PET/CT
  • Quantification
  • Radium
  • Treatment planning
  • Triple-negative metastatic breast cancer
  • Tumour
  • bone metastases
  • breast cancer
  • breast cancer prognosis
  • cancer
  • doi
  • early pet
  • fluoride-PET/CT
  • j nucl med 2016
  • jnumed
  • lymphoma
  • metabolic tumor volume
  • metastatic prostate
  • multicenter clinical trial
  • pet
  • repeatability
  • skeletal tumor burden
  • sodium fluoride
  • standardized uptake value

Cite this